Deng Yamin, Wu Chen, Na Jintong, Tang Jing, Qin Simin, Zhang Zhiyong, Zhong Liping
State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Major New Drugs Innovation and Development, Guangxi Medical University, Nanning, Guangxi, 530021, China.
Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, New Brunswick, NJ, 08901-8554, USA.
Cancer Metastasis Rev. 2025 Jun 25;44(3):57. doi: 10.1007/s10555-025-10273-3.
During the last three decades, there has been substantial advancement in comprehending the chemical attributes and roles of natural killer (NK) cells, resulting in a growing interest in these cells. Simultaneously, the swift advancement of adoptive transfer therapy for immune cells, particularly the impressive achievements of autologous chimeric antigen receptor-T (CAR-T) cells in treating hematological malignant tumors, has fueled interest in using immune cells as a cancer treatment modality and opened the door for NK cell adoptive immunotherapy. NK cell-mediated immunotherapy has shown potential as a readily available, safe, and effective treatment for patients with leukemia. Moreover, clinical studies have demonstrated that NK cell adoptive immunotherapy shows efficacy in various solid tumors and hematologic malignancies, indicating a promising future for this therapeutic approach. This paper will provide an overview of NK cell adoptive therapy, focusing on current clinical trial results and the challenges associated with clinical applications.
在过去三十年中，人们对自然杀伤（NK）细胞的化学特性和作用的理解取得了重大进展，从而引发了对这些细胞越来越浓厚的兴趣。与此同时，免疫细胞过继转移疗法的迅速发展，尤其是自体嵌合抗原受体T（CAR-T）细胞在治疗血液系统恶性肿瘤方面取得的令人瞩目的成就，激发了人们将免疫细胞用作癌症治疗方式的兴趣，并为NK细胞过继免疫疗法打开了大门。NK细胞介导的免疫疗法已显示出作为白血病患者一种现成、安全且有效的治疗方法的潜力。此外，临床研究表明，NK细胞过继免疫疗法在各种实体瘤和血液系统恶性肿瘤中均显示出疗效，这表明这种治疗方法前景广阔。本文将概述NK细胞过继疗法，重点关注当前的临床试验结果以及与临床应用相关的挑战。
